275 related articles for article (PubMed ID: 36980713)
1. Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives.
Ottaiano A; Santorsola M; Circelli L; Trotta AM; Izzo F; Perri F; Cascella M; Sabbatino F; Granata V; Correra M; Tarotto L; Stilo S; Fiore F; Martucci N; Rocca A; Picone C; Muto P; Borzillo V; Belli A; Patrone R; Mercadante E; Tatangelo F; Ferrara G; Di Mauro A; Scognamiglio G; Berretta M; Capuozzo M; Lombardi A; Galon J; Gualillo O; Pace U; Delrio P; Savarese G; Scala S; Nasti G; Caraglia M
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980713
[TBL] [Abstract][Full Text] [Related]
2. Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study.
Ottaiano A; De Luca A; Santorsola M; Scognamiglio G; Di Mauro A; Chiodini P; Lambiase M; Sacco A; Petrillo A; Granata V; Fusco R; Mercadante E; Martucci N; De Luca G; Rocca A; Celentano E; Crispo A; Di Gennaro P; Tatangelo F; Ferrara G; Izzo F; Belli A; Patrone R; Delrio P; Rega D; De Franciscis S; Muto P; Ravo V; Di Franco R; Borzillo V; Santagata S; Rea G; Castaldo D; Pace U; De Feo G; Scala S; Nasti G; Normanno N
BMC Cancer; 2023 Oct; 23(1):1010. PubMed ID: 37858132
[TBL] [Abstract][Full Text] [Related]
3. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document.
Lievens Y; Guckenberger M; Gomez D; Hoyer M; Iyengar P; Kindts I; Méndez Romero A; Nevens D; Palma D; Park C; Ricardi U; Scorsetti M; Yu J; Woodward WA
Radiother Oncol; 2020 Jul; 148():157-166. PubMed ID: 32388150
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic Disease.
Kim J; Chang JS; Sung W; Kim JS; Kim TH; Choi SH; Kim KH; Ko H; Lee HS; Jeon S; Shin SJ; Liu M; Olson R
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):883-891. PubMed ID: 36007725
[TBL] [Abstract][Full Text] [Related]
5. Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers.
Zhao Y; Li J; Li D; Wang Z; Zhao J; Wu X; Sun Q; Lin PP; Plum P; Damanakis A; Gebauer F; Zhou M; Zhang Z; Schlösser H; Jauch KW; Nelson PJ; Bruns CJ
Semin Cancer Biol; 2020 Feb; 60():334-343. PubMed ID: 31445220
[TBL] [Abstract][Full Text] [Related]
6. Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
deSouza NM; Liu Y; Chiti A; Oprea-Lager D; Gebhart G; Van Beers BE; Herrmann K; Lecouvet FE
Eur J Cancer; 2018 Mar; 91():153-163. PubMed ID: 29331524
[TBL] [Abstract][Full Text] [Related]
7. Approach to Oligometastatic Cancer in the Elderly Patient.
Winter IW; Smile TD; Videtic GMM
Curr Oncol Rep; 2021 Aug; 23(11):122. PubMed ID: 34448967
[TBL] [Abstract][Full Text] [Related]
8. Oligo-Metastatic Disease in Oncology: Exploring the Limits and the Potential of Genetic Assessment.
Santorsola M; Capuozzo M; Savarese G; Ianniello M; Petrillo N; Casillo M; Sabbatino F; Perri F; Ferrara F; Zovi A; Berretta M; Granata V; Nasti G; Ottaiano A
Genes (Basel); 2023 Nov; 14(12):. PubMed ID: 38136953
[TBL] [Abstract][Full Text] [Related]
9. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
Moretto R; Rossini D; Zucchelli G; Lonardi S; Bergamo F; Santini D; Cupini S; Tomasello G; Caponnetto S; Zaniboni A; Antoniotti C; Pietrantonio F; Buonadonna A; Marmorino F; Bordonaro R; Fea E; Tamburini E; Boccaccino A; Grande R; Aprile G; Falcone A; Cremolini C
Eur J Cancer; 2020 Nov; 139():81-89. PubMed ID: 32979645
[TBL] [Abstract][Full Text] [Related]
10. Imaging of Oligometastatic Disease.
Vietti Violi N; Hajri R; Haefliger L; Nicod-Lalonde M; Villard N; Dromain C
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326586
[TBL] [Abstract][Full Text] [Related]
11. Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study.
Kroese TE; Takahashi Y; Lordick F; van Rossum PSN; Ruurda JP; Lagarde SM; van Hillegersberg R; Verhoeven RHA; van Laarhoven HWM
Eur J Cancer; 2023 Jan; 179():65-75. PubMed ID: 36509000
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy for metastatic lung metastases.
Kimura T; Fujiwara T; Kameoka T; Adachi Y; Kariya S
Jpn J Radiol; 2022 Oct; 40(10):995-1005. PubMed ID: 36097233
[TBL] [Abstract][Full Text] [Related]
13. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
14. Metastasis-directed Therapy in Prostate Cancer: Prognostic Significance of the ESTRO/EORTC Classification in Oligometastatic Bone Disease.
Nicholls L; Chapman E; Khoo V; Suh YE; Tunariu N; Wang Y; van As N
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):63-69. PubMed ID: 34756755
[TBL] [Abstract][Full Text] [Related]
15. Incidence and survival of patients with oligometastatic esophagogastric cancer: A multicenter cohort study.
Kroese TE; Christ SM; van Rossum PSN; Burger MDL; Buijs GS; Mühlematter U; Andratschke N; Ruurda JP; Hüllner M; Gutschow CA; van Hillegersberg R; Guckenberger M
Radiother Oncol; 2022 Aug; 173():269-276. PubMed ID: 35753555
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
17. Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?
Ottaiano A; Santorsola M; Caraglia M; Circelli L; Gigantino V; Botti G; Nasti G
Transl Oncol; 2021 Aug; 14(8):101131. PubMed ID: 34034007
[TBL] [Abstract][Full Text] [Related]
18. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
19. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis.
Kroese TE; van Laarhoven HWM; Nilsson M; Lordick F; Guckenberger M; Ruurda JP; D'Ugo D; Haustermans K; van Cutsem E; van Hillegersberg R; van Rossum PSN
Eur J Cancer; 2022 May; 166():254-269. PubMed ID: 35339868
[TBL] [Abstract][Full Text] [Related]
20. Is Oligometastatic Cancer Curable? A Survey of Oncologist Perspectives, Decision Making, and Communication.
Cho HL; Balboni T; Christ SM; Turner B; Spektor A; Perni S
Adv Radiat Oncol; 2023; 8(5):101221. PubMed ID: 37124028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
